Trenbolone

A veterinary cattle implant that became the most feared and most meme'd steroid in bodybuilding — dramatic recomposition, and a side-effect profile severe enough that "tren dreams" and "tren rage" are community vocabulary, not marketing.

In preclinical binding work trenbolone has high affinity for the androgen receptor, well above testosterone. That is a laboratory measurement and it is NOT a validated multiplier for human benefit, dose equivalence or harm — nothing licenses converting a binding number into "the harms arrive at the same scale". Unlike almost everything else in this class it cannot be aromatised at all; there is no oestrogen pathway from trenbolone. It also has progesterone-receptor activity in preclinical work, but the popular chain from that to raised prolactin to breast tissue in humans has never been demonstrated — the mechanism behind breast changes on trenbolone is genuinely unknown. It is also not meaningfully converted by 5-alpha reductase, so it reaches tissue as the potent parent compound. Beyond receptor binding it is a nutrient-partitioning agent — the reason cattle feedlots used it in the first place was feed efficiency, converting intake into lean tissue rather than fat.

Zero human clinical development — every human data point is animal agriculture, case reports, or the community. Its androgen-receptor affinity is high in preclinical binding studies, which cannot be converted into a human potency or harm multiplier.

• No credible human therapeutic efficacy trial exists and there is no approved human use. That is not literally no human data: controlled metabolism and elimination studies have administered labelled trenbolone to volunteers. Those measured how the body clears it, not whether it does anything useful or safe.
• The entire evidence base is livestock production data (where the endpoints are carcass yield and feed conversion, not human health) plus veterinary pharmacology.
• Everything else circulating about it — the strength claims, the recomposition claims, the comparative potency numbers — is receptor-binding-affinity data extrapolated into human outcomes it was never measured against, plus self-report.
• The neuropsychiatric effects are the most consistently reported phenomenon associated with it, and they rest on user report and case description rather than controlled study — LIMITED evidence, with true frequency unknown. Recomposition benefit in controlled humans: NONE SHOWN.

Several ester forms circulate and differ substantially in release and elimination; because it is neither aromatised nor 5-alpha reduced, what reaches tissue is essentially the parent compound, and adverse effects and endocrine suppression can outlast measurable drug. It is prohibited in tested sport and produces anti-doping violations. Its distinctive effects — night sweats, sleep disruption, and the acute cough some people get on injection — are associated with the compound rather than any metabolite. That cough should not be normalised: sudden cough or breathlessness after an oily injection can be a manifestation of pulmonary oil microembolism or anaphylaxis, and needs urgent assessment rather than an explanation.

Reported effects include night sweats, insomnia, aggression and anxiety, acute cough or breathlessness on injection, reduced cardiovascular capacity, adverse lipid changes and a substantial mental-health footprint. Grading these honestly: the psychiatric signal is LIMITED (case reports and self-report), and compound-specific rankings for cardiovascular, renal, lipid or recovery severity are NOT established — serious anabolic-steroid class risk is, but no trenbolone-specific frequency or comparative claim survives the evidence. It does not aromatise. There is no medical oversight pathway for a veterinary compound — bloodwork is the only instrument anyone has.

• Class-level severe outcomes reported with anabolic steroids, which no compound here is exempt from: cardiac arrest, heart attack, thickened heart muscle, heart failure and stroke; serious liver injury; and mania, paranoia, psychosis, hostility, aggression, dependence and depression on withdrawal.
• Pregnancy and breastfeeding: androgens can cause fetal harm including virilisation of a female fetus. Avoid in both.
• Anyone with any history of depression, anxiety, psychosis or mood instability — this is the compound in this catalog with the most consistent neuropsychiatric signal.
• Anyone with cardiovascular disease, hypertension, or an already adverse lipid profile.
• Anyone with impaired kidney function.
• Anyone whose sleep is already poor, or whose work and relationships cannot absorb months of irritability and broken sleep.
• Anyone drug-tested at any level of sport.

• Aromatase inhibitors do nothing useful against trenbolone-driven breast tissue changes, because the pathway is prolactin/progesterone rather than estrogen — a mismatch that leads people to escalate a drug that was never going to work.
• Stimulants, caffeine included, stack onto an already elevated heart rate, blood pressure and insomnia load.
• Any other compound that raises prolactin compounds the same problem.
• Combining it with other non-aromatising compounds can drive estradiol low enough that libido and joint symptoms arrive from the deficit rather than any excess.

• Breast tissue changes need clinician assessment for cause — endocrine, medication, liver, kidney and other possibilities — rather than a self-selected hormone test. No human evidence validates the prolactin algorithm that circulates for this compound.
• Lipids — HDL suppression with trenbolone is severe even by anabolic-steroid standards.
• Blood pressure, measured at home and often.
• Dark or brown urine is a PROMPT MEDICAL ASSESSMENT symptom, not something to interpret. It can accompany serious liver injury, muscle breakdown, blood in the urine or kidney injury, and none of those can be told apart by guesswork.
• Sleep quality and mood, tracked honestly and ideally corroborated by someone else — insomnia and irritability are the effects users are least able to self-assess.
• Full hormone panel including LH/FSH, given the depth of suppression.

Suppression is profound and the recovery window is correspondingly rough — the low-testosterone state that follows lands on top of whatever sleep debt and mood disturbance accumulated during use. Night sweats and insomnia typically resolve as the compound clears, on the ester's timeline. The axis is the unpredictable part: heavy or prolonged use here produces some of the slower recoveries in this class, and there is no human data to give an expected duration — only the pattern clinicians describe afterwards.

US: Schedule III, with no FDA-approved human product. Illicit product identity, sterility and composition are unverifiable.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Impact of Either Trendelenburg or Reverse Trendelenburg Positioning for Ureteroscopy Lithotripsy Procedures: A Systematic Review and Meta-Analysis
  J Urol, 2025
• Impact of trenbolone on selected organs
  Endokrynol Pol, 2024
• Examining the association between trenbolone, psychological distress, and aggression among males who use anabolic-androgenic steroids
  Int J Drug Policy, 2024

• Impact of trenbolone on selected organsEndokrynol Pol · 2024
• Trenbolone: application of the Ames test. Recent dataAnn Rech Vet · 1991
• Environmental fate and effects of 17α-trenbolone and 17α-estradiol: IntroductionEnviron Toxicol Chem · 2017
• Melatonin attenuates 17β-trenbolone induced insomnia-like phenotype and movement deficiency in zebrafishChemosphere · 2020
• 17β-Trenbolone activates androgen receptor, upregulates transforming growth factor beta/bone morphogenetic protein and Wnt signaling pathways, and induces masculinization of caudal and anal fins in female guppies (Poecilia reticulata)Aquat Toxicol · 2023
• Examining the association between trenbolone, psychological distress, and aggression among males who use anabolic-androgenic steroidsInt J Drug Policy · 2024
• 17β-Trenbolone binds to androgen receptor, decreases number of primordial germ cells, modulates expression of genes related to sexual differentiation, and affects sexual differentiation in zebrafish (Danio rerio)Sci Total Environ · 2022
• Influence of Bisphenol A and 17β-Trenbolone Exposure in Oryzias CongenersEnviron Toxicol Chem · 2023
• Localized surface plasmon resonance sensing of Trenbolone acetate dopant using silver nanoparticlesSci Rep · 2024
• Effect of 17β-trenbolone exposure during adolescence on the circadian rhythm in male miceChemosphere · 2022
• Transcriptomic profiling as a screening tool to detect trenbolone treatment in beef cattleRes Vet Sci · 2014
• Sorption and desorption of 17α-trenbolone and trendione on five soilsEnviron Toxicol Chem · 2017